Clinical Trial Update: TDENV PIV and LAV Dengue Prime-boost Strategy Using AS03B Adjuvant [Phase 1]

View source ↗

Summary

A Phase 1 dengue vaccine trial evaluating a TDENV PIV and LAV prime-boost strategy with AS03B adjuvant has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue

Drugs mentioned

• LAV Dengue
• TDENV PIV

Snippet

Sponsor: U.S. Army Medical Research and Development Command | Conditions: Dengue | Phase 1 | Status: WITHDRAWN